CLINICAL STUDY
In-stent restenosis in small coronary arteries
Impact of strut thickness
Carlo Briguori, MD, PhD*,
Cristiano Sarais, MD*,
Paolo Pagnotta, MD*,
Francesco Liistro, MD*,
Matteo Montorfano, MD*,
Alaide Chieffo, MD*,
Fabio Sgura, MD*,
Nicola Corvaja, MD ,
Remo Albiero, MD,
Goran Stankovic, MD,
Costantinos Toutoutzas, MD,
Erminio Bonizzoni, PhD ,
Carlo Di Mario, MD, PhD, FACC* and
Antonio Colombo, MD, FACC*,*
* Laboratory of Interventional Cardiology, "Vita e Salute" University School of Medicine, San Raffaele Hospital, Milan, Italy
EMO Centro Cuore Columbus, Milan, Italy
Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
Manuscript received February 5, 2002;
revised manuscript received March 25, 2002,
accepted April 17, 2002.
* Reprint requests and correspondence: Dr. Antonio Colombo, EMO Centro Cuore Columbus, Via Buonarroti 48, 20145 Milan, Italy.
columbus{at}micronet.it
OBJECTIVES: We sought to evaluate whether strut thickness may impact the restenosis rate after stent implantation in small coronary arteries.
BACKGROUND: Small vessel size (<3.0 mm) is an independent risk factor for the occurrence of in-stent restenosis. It has been reported that vessel damage induced during stent deployment is an important factor in restenosis.
METHODS: From our database, we selected all patients who had successful stenting in small native vessels, with angiographic follow-up available, between March 1996 and April 2001. The strut was defined as thin when <0.10 mm and thick when  0.10 mm. According to these criteria, we identified two subgroups: a thin group and a thick group.
RESULTS: A total of 821 (57%) of the 1,447 patients had angiographic follow-up available and were included in the analysis. The thin group included 400 patients with 505 lesions. The thick group included 421 patients with 436 lesions. The restenosis rate was 28.5% in the thin group and 36.6% in the thick group (p = 0.009; odds ratio [OR] 1.44, 95% confidence interval [CI] 1.09 to 1.90). The study group was classified into three subgroups according to the reference vessel diameter:  2.50 mm, 2.51 to 2.75 mm and 2.76 to 2.99 mm. Strut thickness influenced the restenosis rate only in the subgroup with a reference vessel diameter between 2.76 and 2.99 mm, with rates of 23.5% in the thin group and 37% in the thick group (p = 0.006). By logistic regression analysis, predictors of restenosis were stent length (OR 1.03, 95% CI 1.01 to 1.04; p = 0.001), strut thickness (OR 1.68, 95% CI 1.23 to 2.29; p = 0.001) and diabetes mellitus (OR 2.10, 95% CI 1.21 to 3.68; p = 0.007).
CONCLUSIONS: This study supports that strut thickness is an independent predictor of restenosis in coronary arteries with a reference diameter of 2.75 to 2.99 mm.
|
Abbreviations and Acronyms
| | CI | | confidence interval | | DS | | diameter stenosis | | OR | | odds ratio | | MACE | | major acute cardiac events | | MLD | | minimal lumen diameter |
|
This article has been cited by other articles:
|
|
|
|
 
M. A. Turco, J. A. Ormiston, J. J. Popma, J. J. Hall, T. Mann, L. A. Cannon, M. W.I. Webster, G. J. Mishkel, C. D. O'Shaughnessy, T. F. McGarry, et al.
Reduced Risk of Restenosis in Small Vessels and Reduced Risk of Myocardial Infarction in Long Lesions With the New Thin-Strut TAXUS Liberte Stent: 1-Year Results From the TAXUS ATLAS Program
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
699 - 709.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. I. Levy, J. Mocco, R. M. Samuelson, R. D. Ecker, B. S. Jahromi, and L. N. Hopkins
Optimal treatment of carotid artery disease.
J. Am. Coll. Cardiol.,
March 11, 2008;
51(10):
979 - 985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Jaffery, M. Kowalski, W. D. Weaver, and S. Khanal
A meta-analysis of randomized control trials comparing minimally invasive direct coronary bypass grafting versus percutaneous coronary intervention for stenosis of the proximal left anterior descending artery
Eur. J. Cardiothorac. Surg.,
April 1, 2007;
31(4):
691 - 697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehilli, A. Dibra, A. Kastrati, J. Pache, J. Dirschinger, A. Schomig, and for the Intracoronary Drug-Eluting Stenting to Abr
Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels
Eur. Heart J.,
February 1, 2006;
27(3):
260 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pache, A. Dibra, J. Mehilli, J. Dirschinger, A. Schomig, and A. Kastrati
Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial
Eur. Heart J.,
July 1, 2005;
26(13):
1262 - 1268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Moreno, C. Fernandez, F. Alfonso, R. Hernandez, M. J. Perez-Vizcayno, J. Escaned, M. Sabate, C. Banuelos, D. J. Angiolillo, L. Azcona, et al.
Coronary stenting versus balloon angioplasty in small vessels: A meta-analysis from 11 randomized studies
J. Am. Coll. Cardiol.,
June 2, 2004;
43(11):
1964 - 1972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Lemos, A. Hoye, D. Goedhart, C. A. Arampatzis, F. Saia, W. J. van der Giessen, E. McFadden, G. Sianos, P. C. Smits, S. H. Hofma, et al.
Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex Patients: An Evaluation From the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Study
Circulation,
March 23, 2004;
109(11):
1366 - 1370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
